THE CLIENT
Dextenza® – the flagship prescription medication from Ocular Therapeutix – is an ophthalmic insert used in the operating room and office to treat ocular inflammation and pain following ophthalmic surgery. DEXTENZA provides an opportunity for physicians to alleviate their patients of the burden of administration of their post-op steroid drop regimen. One insert can replace the need for ~70 steroid eye drops.
THE PROJECT
To announce the FDA’s approval of a new indication for the use in patients with ocular itching associated with allergic conjunctivitis, the team at Ocular collaborated with Stark / Raving to update and enhance their direct-to-physician marketing activities. The development of a combination of offline and digital tactics helped support a successful launch for this new use.
